NCT00378560View on ClinicalTrials.gov

V501 Efficacy Study in Women Aged 18 to 26 (V501-027)

PHASE2CompletedINTERVENTIONAL
Enrollment

1,021

Participants

Timeline

Start Date

June 12, 2006

Primary Completion Date

September 16, 2009

Study Completion Date

September 16, 2009

Conditions
HPV Infections
Interventions
BIOLOGICAL

Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine

V501; Gardasil, 0.5 ml injection in 3 dosing regimen

BIOLOGICAL

Comparator: Placebo

Placebo 0.5 ml injection in 3 dosing regimen

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00378560 - V501 Efficacy Study in Women Aged 18 to 26 (V501-027) | Biotech Hunter | Biotech Hunter